IL-17A in the tumor microenvironment of the human colorectal adenoma–carcinoma sequence

Cui, Guanglin; Yuan, Ang; Goll, Rasmus; Florholmen, Jon

doi:10.3109/00365521.2012.725089

Cited by 64 publications

(54 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-17A is continuously increased at the cancer stage, but is not associated with CRC patients' clinical pathological features. 31 In addition, we are also able to show that the stimulator factors (cytokines) for Th17 differentiation and expansion are also increased in the same patterns as IL-17A along the whole sequence, 31 indicating that increased IL-17A is probably from the activated Th17 cells. Thus, our findings suggest that the activation of Th17 cells may affect both the adenoma stage and cancer stage.…”

Section: Il-17a Promotes Formation Of Precancerous Adenoma and Initiamentioning

confidence: 86%

“…29 Many changes including genetic, molecular, and histological alterations have been observed along the progression from human colorectal adenoma to CRC, 30 we have therefore examined that the expression level of IL-17A and Th17 cellstimulating factors (cytokines) both at the precancerous stage and cancerous stage. 31 We have found that the expression level of IL-17A is significantly elevated from the adenoma stage and throughout to the cancer stage. 31 At the adenoma stage, the expression level of IL-17A in the microenvironment is associated with the severity of dysplasia that has been recognized as one of the histological hallmark for cancer risk in patients with adenoma.…”

Section: Il-17a Promotes Formation Of Precancerous Adenoma and Initiamentioning

confidence: 97%

“…31 We have found that the expression level of IL-17A is significantly elevated from the adenoma stage and throughout to the cancer stage. 31 At the adenoma stage, the expression level of IL-17A in the microenvironment is associated with the severity of dysplasia that has been recognized as one of the histological hallmark for cancer risk in patients with adenoma. IL-17A is continuously increased at the cancer stage, but is not associated with CRC patients' clinical pathological features.…”

Section: Il-17a Promotes Formation Of Precancerous Adenoma and Initiamentioning

confidence: 97%

“…Although the expression level of IL-17A at the cancer is even higher, it is not related to the TNM parameters of CRC. 31 Our findings may raise an interesting possibility that the dominant role of IL-17A in regulating the development of CRC is on the precancerous stage. However, it remains further studied and confirmed.…”

mentioning

confidence: 95%

“…44 It is unknown whether IL-17 can enhance the production of IL-8 from CRC cells, however, both IL-17 and IL-8 have been found to be increased in patients with CRC. 5,31,45,46 It is necessary to further investigate whether IL-17A can stimulate IL-8 released from CRC cells in patients with CRC.…”

mentioning

confidence: 99%

See 4 more Smart Citations

The Role of Interleukin-17A in Colorectal Tumorigenesis

Shi

Lin²,

Cui³

et al. 2013

Cancer Biotherapy and Radiopharmaceuticals

Self Cite

View full text Add to dashboard Cite

It has been well documented that interleukin (IL)-17A mainly produced by the newly identified T cell subtype Th17 cells is an important proinflammatory cytokine that plays a vital pathogenic role in the process of human inflammatory bowel diseases. Recently, new information concerning the biological activities of IL-17A relating to the development of colorectal cancer (CRC) has also been reported. The present mini-review focuses on recent observations concerning the role of IL-17A in the development of CRCs, and it discusses the clinical significance of IL-17A as a biomarker and potential therapeutic target.

show abstract

Section: Il-17a Promotes Formation Of Precancerous Adenoma and Initiamentioning

confidence: 86%

Section: Il-17a Promotes Formation Of Precancerous Adenoma and Initiamentioning

confidence: 97%

Section: Il-17a Promotes Formation Of Precancerous Adenoma and Initiamentioning

confidence: 97%

mentioning

confidence: 95%

mentioning

confidence: 99%

See 3 more Smart Citations

The Role of Interleukin-17A in Colorectal Tumorigenesis

Shi

Lin²,

Cui³

et al. 2013

Cancer Biotherapy and Radiopharmaceuticals

Self Cite

View full text Add to dashboard Cite

show abstract

Cytokine‐ and chemokine‐induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy

Bhat

Nisar

Singh

et al. 2022

Cancer Communications

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a predominant life‐threatening cancer, with liver and peritoneal metastases as the primary causes of death. Intestinal inflammation, a known CRC risk factor, nurtures a local inflammatory environment enriched with tumor cells, endothelial cells, immune cells, cancer‐associated fibroblasts, immunosuppressive cells, and secretory growth factors. The complex interactions of aberrantly expressed cytokines, chemokines, growth factors, and matrix‐remodeling enzymes promote CRC pathogenesis and evoke systemic responses that affect disease outcomes. Mounting evidence suggests that these cytokines and chemokines play a role in the progression of CRC through immunosuppression and modulation of the tumor microenvironment, which is partly achieved by the recruitment of immunosuppressive cells. These cells impart features such as cancer stem cell‐like properties, drug resistance, invasion, and formation of the premetastatic niche in distant organs, promoting metastasis and aggressive CRC growth. A deeper understanding of the cytokine‐ and chemokine‐mediated signaling networks that link tumor progression and metastasis will provide insights into the mechanistic details of disease aggressiveness and facilitate the development of novel therapeutics for CRC. Here, we summarized the current knowledge of cytokine‐ and chemokine‐mediated crosstalk in the inflammatory tumor microenvironment, which drives immunosuppression, resistance to therapeutics, and metastasis during CRC progression. We also outlined the potential of this crosstalk as a novel therapeutic target for CRC. The major cytokine/chemokine pathways involved in cancer immunotherapy are also discussed in this review.

show abstract

Fusobacterium nucleatum and colorectal cancer: A mechanistic overview

Goradel

Heidarzadeh

Jahangiri

et al. 2018

Journal Cellular Physiology

137

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most prevalent cancer in the world. There are many risk factors involved in CRC. According to recent findings, the tumor microenvironment and feces samples of patients with CRC are enriched by Fusobacterium nucleatum. Thus, F. nucleatum is proposed as one of the risk factors in the initiation and progression of CRC. The most important mechanisms of Fusobacterium nucleatum involved in CRC carcinogenesis are immune modulation (such as increasing myeloid‐derived suppressor cells and inhibitory receptors of natural killer cells), virulence factors (such as FadA and Fap2), microRNAs (such as miR‐21), and bacteria metabolism. The aim of this review was to evaluate the mechanisms underlying the action of F. nucleatum in CRC.

show abstract

IL-17A in the tumor microenvironment of the human colorectal adenoma–carcinoma sequence

Abstract: IL-17A and TH17 are highly activated throughout the colorectal adenoma-carcinoma sequence.

Cited by 64 publications

References 42 publications

The Role of Interleukin-17A in Colorectal Tumorigenesis

The Role of Interleukin-17A in Colorectal Tumorigenesis

Cytokine‐ and chemokine‐induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy

Fusobacterium nucleatum and colorectal cancer: A mechanistic overview

Contact Info

Product

Resources

About